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Objectives The aim of this study was to evaluate the association between calculated creatinine clearance (CCC)-based con-
trast dose and renal complications in patients undergoing percutaneous coronary interventions (PCI).
Background Excess volumes of contrast media are associated with renal complications in patients undergoing cardiac proce-
dures. Because contrast media are excreted by the kidney, we hypothesized that a dose estimation on the basis
of CCC would provide a simple strategy to define a safe dose of contrast media.
Methods We assessed the association between CCC-based contrast dose and the risk of contrast-induced nephropathy
(CIN) and need for in-hospital dialysis in 58,957 patients undergoing PCI and enrolled in the BMC2 (Blue Cross
Blue Shield of Michigan Cardiovascular Consortium) registry from 2007 to 2008. Patients receiving dialysis at
the time of the procedure were excluded.
Results The risk of CIN and nephropathy requiring dialysis (NRD) was directly associated with increasing contrast volume
adjusted for renal function. The risk for CIN and NRD approached significance when the ratio of contrast dose/
CCC exceeded 2 (adjusted odds ratio [OR] for CIN: 1.16, 95% confidence interval [CI]: 0.98 to 1.37, adjusted OR
for NRD: 1.72, 95% CI: 0.9 to 3.27) and was dramatically elevated in patients exceeding a contrast to CCC ratio
of 3 (adjusted OR for CIN: 1.46, 95% CI: 1.27 to 1.66, adjusted OR for NRD: 1.89, 95% CI: 1.21 to 2.94).
Conclusions Our study supports the need for minimizing contrast dose in patients with renal dysfunction. A contrast dose on
the basis of estimated renal function with a planned contrast volume restricted to less than thrice and prefera-
bly twice the CCC might be valuable in reducing the risk of CIN and NRD. (J Am Coll Cardiol 2011;58:907–14)
© 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.05.023Contrast-induced nephropathy (CIN) is a common, serious
problem of percutaneous coronary intervention (PCI) that is
associated with increased morbidity, mortality, and health
From the *Department of Internal Medicine, Division of Cardiovascular Medicine,
University of Michigan Medical Center, Ann Arbor, Michigan; †Department of
Cardiovascular Medicine, Beaumont Healthcare, Royal Oak, Michigan; ‡Depart-
ment of Internal Medicine, St. John Hospital, Detroit, Michigan; §Department of
Internal Medicine, Henry Ford Hospital, Detroit, Michigan; and the Department of
Medicine, University of Miami Medical Center, Miami, Florida. The BMC2 (Blue
Cross Blue Shield of Michigan Cardiovascular Consortium) registry is funded by Blue
Cross Blue Shield of Michigan (BCBSM) and Blue Care Network, with initial
registry development funded by the BCBSM Foundation. The sponsor had no role in
study design, analysis, or the decision to present or publish these findings. Dr. Gurm
has received research funding from BCBSM and the National Institute of Health. Dr.
Dixon has received research support from Abbott Vascular, Abiomed, and Infraredx.
Dr. Share is employed by BCBSM. Dr. LaLonde is on the speakers’ bureau for
Abbott Vascular, Gilead Sciences, Pfizer, and GlaxoSmithKline; and has received
research support from Medtronic. Dr. Moscucci has received research support from
BCBSM in the past. All other authors have reported that they have no relationships
relevant to the contents of this paper to disclose.Manuscript received February 16, 2011; revised manuscript received May 20, 2011,
accepted May 24, 2011.care cost (1–4). Conditions that heighten the risk of CIN
such as chronic kidney disease, diabetes, congestive heart
failure, hemodynamic instability, and anemia are not typi-
cally modifiable at the time of cardiac catheterization, but
other strategies have emerged to minimize the nephrotox-
icity of contrast media (4,5).
Proven effective preventative measures against CIN in
PCI patients include hydration with normal saline and
minimization of contrast volume (CV) (6,7). The benefit of
N-acetylcysteine or isotonic sodium bicarbonate remains
controversial, with considerable disagreement between var-
ious studies and meta-analysis (8–11).
Although the need to minimize contrast is generally
recognized, it remains unclear as to what is a safe level of
contrast. Prior studies support use of maximal acceptable
contrast dose (MACD) to determine the threshold for
safe contrast exposure customized to each patient (12). The
MACD is calculated by 5 ml of contrast·body weight
(kg)/baseline serum creatinine (mg/dl). Although MACD
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(13,14), it is infrequently used in
clinical practice. Furthermore, a
significant number of cases of CIN
occur even when MACD is not
exceeded. Contrast media are
excreted via kidneys, and one
possible alternative method for
contrast dosing would be to
calculate CV on the basis of
renal function (15).
The purpose of this investiga-
tion is: 1) to assess whether con-
trast dose on the basis of calculated
creatinine clearance (CCC) is bet-
ter than MACD at predicting
CIN and need for dialysis; and 2)
to define the safe dose of contrast
media on the basis of CCC.
Methods
The study cohort for our analysis included patients under-
going PCI in a large regional registry of contemporary PCI
in 31 hospitals in Michigan. The details of the registry and
of the data collection process have been described previously
(16–18). Briefly, procedural data on all patients undergoing
elective and nonelective PCI at the participating hospitals
are collected with standardized data collection forms. Base-
line data include clinical, demographic, procedural, and
angiographic characteristics as well as medications used
before, during, and after the procedure and in-hospital
outcomes. All data elements have been prospectively de-
fined, and the protocol was approved by the local institu-
tional review board at each institution. The data were
collected by a dedicated staff member and forwarded to the
coordinating center. Medical records of all patients under-
going multiple procedures or coronary artery bypass grafting
or of patients who died in the hospital were reviewed to
ensure data accuracy. A further 2% of cases were randomly
selected for audit.
The study population for this analysis included 58,957
patients who underwent PCI from 2007 to 2008. We
excluded patients with a prior history of renal failure
requiring dialysis and patients with missing baseline or
post-procedural creatinine measurement. All procedures
were performed with standard coronary intervention tech-
nique. The choice of contrast media was at the discretion of
the operating physician within the dictates of the individual
hospital policy.
The primary endpoints for this analysis were CIN and
nephropathy requiring dialysis (NRD). CIN was defined as
impairment in renal function resulting in 0.5 mg/dl
absolute increase in serum creatinine from baseline. Peak
creatinine was defined as the highest value of creatinine in
Abbreviations
and Acronyms
CCC  calculated
creatinine clearance
CI  confidence interval
CIN  contrast-induced
nephropathy
CV  contrast volume
GFR  glomerular filtration
rate
MACD  maximal
acceptable contrast dose
MDRD  Modification of
Diet in Renal Disease
NRD  nephropathy
requiring dialysis
OR  odds ratio
PCI  percutaneous
coronary interventionthe week after the procedure and was ascertained as per localclinical practice. A follow-up creatinine was collected at
least 1 day after the procedure but varied, depending on
length of stay. NRD was defined as new need for hemodi-
alysis in patients due to worsening of renal function after
PCI. The CCC was calculated with the Cockcroft-Gault
equation (19). We also assessed the utility of using contrast
dose on the basis of glomerular filtration rate (GFR) as
estimated by the Modification of Diet in Renal Disease
(MDRD) equation (20). Because Cockcroft-Gault equation
has been conventionally used for renal dosing of medica-
tions, these results are preferentially reported (21).
Continuous variables are expressed as mean  SD, and
discrete variables are expressed as frequency counts and
percentages. The differences in discrete variables between
groups were evaluated by the chi-square test and Fisher’s
exact test. Continuous variables were analyzed with the
t test and Wilcoxon rank-sum test as needed. We estimated
area under the receiver-operator characteristic curve (a plot
of sensitivity vs. 1-specificity) for comparing MACD and
CV/CCC and CV/MDRD GFR for CIN and NRD and
compared them with bootstrapping (22,23). We then plot-
ted the occurrence of CIN and NRD by deciles of CV/
CCC. On the basis of the results of this analysis and to
develop a clinically easy-to-use tool, we divided the cohort
into patients on the basis of CV/CCC of 2, 2 to 2.9, and
3. Rates of CIN were calculated for these categories in the
entire cohort, patients undergoing primary PCI for ST-
segment elevated myocardial infarction or non–ST-segment
elevated myocardial infarction (excluding shock), patients
with cardiogenic shock, patients undergoing PCI for stable
disease, and patients categorized by baseline CCC. Patients
with stable disease were defined as patients who did not
have a myocardial infarction within 7 days; were not in
cardiogenic shock; and had not had a recent cardiac arrest or
had not needed intravenous nitroglycerine, intravenous
unfractionated heparin, low molecular weight heparin, or
platelet glycoprotein IIb/IIIa inhibitors before the proce-
dure. Finally, we calculated the odds of CIN and NRD at
CV/CCC ratio of 2, 2.5, and 3 in unadjusted and fully adjusted
hierarchical models. All analysis was performed with SAS
software (version 9.2, SAS, Cary, North Carolina).
Results
A total of 58,957 patients underwent PCI during the study
period. Patients with end-stage renal disease requiring
dialysis and patients with CV/CCC 10 were excluded
from the analysis, and therefore the total cohort comprised
54,526 patients. A total of 9,097 patients were excluded
from the CIN calculation, because the post-procedural
creatinine was not drawn. Patients who were excluded were,
in general, less sick, less likely to present with acute coronary
syndromes, and had less-advanced coronary artery disease,
compared with the study cohort (Online Table 1). Overall
CIN occurred in 1,470 patients, whereas NRD developed in
142 patients.
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August 23, 2011:907–14 Safe Volume of Contrast Medium in PCIThe mean contrast dose was 205 ml, whereas the median
contrast dose was 200 ml (interquartile range: 100 ml) and
ranged from 5 to 900 ml. The baseline characteristics of
patients who developed CIN compared with those who did
not develop CIN are listed in Table 1. Patients who
developed CIN were typically older, female, and less likely
to be current smokers. The CIN patients were more likely to
have hypertension, prior myocardial infarct, diabetes,
chronic heart failure, extra-cardiac vascular diseases, signif-
icant valve diseases, history of gastrointestinal bleeding,
atrial fibrillation, and chronic obstructive airways disease.
The CIN patients were more likely to have worse renal
function at baseline, anemia, and a lower ejection fraction.
Baseline Characteristics of Patients Who Developed CIN or NRDTable 1 Baseline Characteristics of Patients Who Developed C
Risk Factor CIN (n  1,470) No CIN (n  43
Demographic
Age (60–69 yrs) 25.6 28.6
Age (70–79 yrs) 29.1 22.8
Age (80 yrs) 25.0 12.0
Female 45.3 33.7
Current smoking 21.8 27.7
Lean (BMI 25 kg/m2) 20.0 18.5
Overweight (BMI 25–29.9 kg/m2) 32.2 35.5
Obese (BMI 30 kg/m2) 48.0 46.1
Historical
Hypertension 89.1 83.4
Prior MI 39.8 34.4
Diabetes 55.2 34.9
Congestive heart failure 38.3 15.2
Extracardiac vascular disease 43.6 25.7
Significant valve disease 10.7 3.8
Gastrointestinal bleeding 4.4 1.6
Atrial fibrillation 22.8 10.1
Cardiac arrest 1.4 1.3
Prior PCI 40.1 44.3
Prior CABG 21.2 19.4
COPD 31.5 19.2
Laboratory
Baseline creatinine 1.5 mg/dl 33.3 9.7
Anemia 55.7 27.2
Ejection fraction 50% 61.7 31.0
Procedural
Emergency PCI 36.7 15.4
MI (prior 7 days) 62.6 32.3
Acute MI (24 h) 38.3 19.5
Recent cardiac arrest 6.3 1.3
Cardiogenic shock 14.1 1.3
Ventricular tachycardia/fibrillation 5.9 1.2
Exceeding MACD 15.0 4.5
Left main stenosis 70% 7.6 3.6
Restenotic lesion 9.7 10.3
Visible thrombus 24.6 12.4
Calcification 16.6 12.2
Chronic total occlusion 1.6 2.1
Values are %. Baseline characteristics of patients who developed contrast-induced nephropathy (C
are excluded.
BMI  body mass index; CABG  coronary artery bypass graft surgery; COPD  chronic obstruc
ercutaneous coronary intervention.They were more likely to be undergoing PCI as an emer-
gency and to have more extensive coronary artery disease
and to be undergoing PCI for cardiogenic shock. Patients
who developed NRD were more likely to have a higher
preponderance of these comorbidities and worse cardiovas-
cular profile (Table 1).
A comparison of area under the receiver-operator char-
acteristic curve demonstrated that CV/CCC was a better
predictor of CIN compared with MACD (c 0.667 vs. c
.632, p  0.05), as well as NRD (c  0.729 vs. c  0.583,
p  0.05). The CV/CCC was similar to CV/MDRD GFR
with respect to predicting CIN (c  0.667 vs. c  0.661,
 0.05) and NRD (c  0.72 vs. c  0.77, p  0.05).
NRD
p Value NRD (n  142) No NRD (n  54,384) p Value
0.01 33.1 28.7 0.25
0.0001 28.9 23.2 0.11
0.0001 16.9 11.9 0.07
0.0001 40.9 34.0 0.09
0.0001 23.2 27.4 0.26
0.13 19.0 18.2 0.79
0.009 28.9 35.3 0.11
0.16 52.1 46.6 0.18
0.0001 84.5 83.8 0.05
0.0001 44.4 34.9 0.005
0.0001 63.4 35.2 0.0001
0.0001 45.1 15.2 0.0001
0.0001 45.1 25.8 0.0001
0.0001 14.8 3.7 0.0001
0.0001 4.9 1.5 0.0009
0.0001 25.4 10.0 0.0001
0.65 0.7 1.3 0.54
0.001 34.5 45.5 0.009
0.09 23.2 19.6 0.27
0.0001 30.3 19.5 0.001
0.0001 62.0 9.6 0.0001
0.0001 65.5 26.7 0.0001
0.0001 73.2 30.3 0.0001
0.0001 52.1 14.0 0.0001
0.0001 73.9 30.1 0.0001
0.0001 51.4 17.9 0.0001
0.0001 11.3 7.3 0.0001
0.0001 28.2 1.5 0.0001
0.0001 10.6 1.2 0.0001
0.0001 21.1 4.5 0.0001
0.0001 11.3 3.6 0.0001
0.40 8.5 10.3 0.48
0.0001 35.2 11.5 0.0001
0.0001 12.7 12.7 0.98
0.69 3.5 2.1 0.25
phropathy requiring dialysis (NRD). Patients with a prior history of renal disease requiring dialysis
lmonary disease; MACD  maximal acceptable contrast dose; MI  myocardial infarction; PCI IN or
,959)
IN) or ne
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Safe Volume of Contrast Medium in PCI August 23, 2011:907–14Figure 1 The Incidence of Contrast-Induced Nephropathy and Nephropathy Requiring Dialysis by Deciles of CV/CCC
The numbers under the solid bars reflect the contrast volume/calculated creatinine clearance (CV/CCC) in each decile.Figure 2 Incidence of CIN and NRD
Incidence of contrast-induced nephropathy (CIN) (A) and nephropathy requiring dialysis (NRD) (B) by categories
of contrast volume/calculated creatinine clearance (CV/CCC) of 2, 2 to 2.9, and 3 in the entire study population.
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August 23, 2011:907–14 Safe Volume of Contrast Medium in PCIThe incidence of CIN and need for dialysis in patients
who underwent PCI was directly but nonlinearly associated
with increasing CV adjusted for renal function (Fig. 1).
When the cohort was divided into deciles of CV/CCC, a
low risk of CIN was evident even among patients exposed to
very low volume of contrast/CCC. The risk for CIN and need
for dialysis increased when the ratio of contrast dose/CCC
exceeded 2 and was dramatically elevated in patients with a
contrast/CCC ratio of 3 (Figs. 2A and 2B).
When the risk for CIN and NRD was assessed in the
ubsets of patients presenting with shock, those undergoing
rimary PCI for ST-segment elevated myocardial infarction
nd those undergoing elective PCI, similar relationship was
bserved—although the absolute incidence of CIN was
ower in more stable patients (Fig. 3).
When the patients were categorized by baseline GFR (30,
0 to 59, 60 to 89, or90 ml/min), the incidence of CIN and
RD increased with worsening GFR (Fig. 4). Within each
ub-cohort defined by baseline GFR, the incidence of CIN
nd NRD was the highest in patients with CV/CCC ratio3.
o significant interaction was observed between the categories
f CV/CCC and the categories of GFR.
Figure 3 Incidence of CIN and NRD by Categories of CV/CCC i
The Y axis scale is different in each category and reflects the difference in baselin
NSTEMI  non–ST-segment elevated myocardial infarction; PCI  percutaneous co
ations as in Figure 2.After adjusting for baseline clinical and other procedural
ariables and for clustering, the CV/CCC ratio remained an
ndependent predictor of CIN and NRD with worsening odds
f CIN and NRD with rising CV/CCC (Fig. 5). The risk for
IN and NRD approached significance when the ratio of
ontrast dose/CCC exceeded 2 (adjusted odds ratio [OR] for
IN: 1.16, 95% confidence interval [CI]: 0.98 to 1.37, p 
.08; adjusted OR for NRD: 1.72, 95% CI: 0.9 to 3.27, p 
.10) and was dramatically elevated in patients exceeding a
ontrast/CCC ratio of 3 (adjusted OR for CIN: 1.46, 95% CI:
.27 to 1.66, p  0.0001; adjusted OR for NRD: 1.89, 95%
I: 1.21 to 2.94, p  0.005).
When the same analysis was repeated with MDRD
quation-derived GFR, the results were similar (Online Figs. 1
nd 2).
iscussion
he key finding of our study is that the CV/CCC ratio is a
imple tool that can help guide contrast dosing in patients
ndergoing PCI. The CV/CCC ratio was superior to MACD
n discriminating between patients most likely to develop CIN,
nd a CV/CCC ratio of under 2 is associated with a low
ious Subgroups
among different subgroups. GFR  glomerular filtration rate;
intervention; STEMI  ST-segment elevated myocardial infarction; other abbrevi-n Var
e risk
ronary
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Safe Volume of Contrast Medium in PCI August 23, 2011:907–14incidence of CIN, whereas the risk of CIN and NRD is
markedly increased when the ratio exceeds 3. Our findings
corroborate and significantly extend prior work in the field.
Because creatinine clearance is routinely calculated for patients
undergoing invasive cardiac procedures, use of CV/CCC ratio
can be easily incorporated into clinical practice and has the
possible implication of impacting patient outcome.
The morbidity and health care cost associated with CIN has
been highlighted in many studies (4,24–26). Methods to
reduce CIN aside from saline hydration and avoidance of high
osmolar contrast media remain controversial, despite extensive
clinical investigation. There are conflicting data on use of
iso-osmolar contrast media, N-acetylcysteine, ascorbic acid,
fenoldopam, sodium bicarbonate infusion, atrial natriuretic
peptide infusion, and prophylactic hemodialysis (25,27,28).
Multiple moderate-sized studies have implicated CV as a
key risk factor for CIN in patients undergoing PCI and have
supported the use of a threshold of 5 body weight/serum
creatinine as the safe upper limit for contrast (13,14). However,
contrast-induced injury has been anecdotally demonstrated at
lower doses of contrast, and the need for better dosing strategy
has been recognized for a long time. Laskey et al. (15) were the
first to propose the use of CV/creatinine clearance ratio and
suggested that volume/creatinine clearance3.7 had the most
optimal sensitivity and specificity for defining CIN. Our study,
Figure 4 Incidence of CIN and NRD by Categories of CV/CCC A
The baseline glomerular filtration rate (GFR) is a key determinant of risk of CIN anhowever, focused on defining a dose range where patient safetycould be optimized further, because even Laskey et al. (15)
recognized that a small but significant number of patients will
develop CIN when the CV/CCC ratio is 3.7. Our data
suggest that efforts to reduce contrast nephrotoxicity need to
focus on efforts to implement a policy of as low as reasonably
possible for contrast media.
Use of CV/CCC ratio follows from basic pharmacological
principles, and our data demonstrate a consistent relationship
between CV/CCC ratio and the risk of CIN and NRD in
multiple subgroups. Furthermore, the inherent simplicity of
calculating CV/CCC ratio makes this an easy construct to
implement in routine clinical practice.
Measures to reduce CV have been described by many
authors in the past and have been a major quality effort for the
BMC2 (Blue Cross Blue Shield of Michigan Cardiovascular
Consortium) registry (17). Recently, Nayak et al. (29) reported
an ultra-low contrast technique that further extends this
principal to prevent CIN. Their technique employs routine
biplane angiography, use of adjunctive imaging such as intra-
vascular ultrasound guidance, “dry” fluoroscopic imaging, and
careful minimization of the contrast administered/injection.
They report completion of diagnostic and therapeutic coronary
procedure with extremely low volume of contrast media, and
wider adoption of their methodology needs to be explored.
Dose of contrast media is but one of the factors that
s Different Categories of Baseline GFR
with higher risk in patients with low baseline GFR. Abbreviations as in Figure 2.cros
d NRDinfluences the risk of CIN in this patient population. Baseline
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August 23, 2011:907–14 Safe Volume of Contrast Medium in PCIcomorbidities, hemodynamic instability, use of other nephro-
toxic agents, and additional patient specific factors probably
interact in a unique fashion to increase the risk of CIN for a
given patient. The results of our study suggest that the baseline
risk of CIN is further influenced by the volume of contrast
media administered and is higher when large volumes of
adjusted contrast media are used.
Study limitations. The BMC2-PCI registry is a regional
database from the state of Michigan with an active focus on
multicentric quality improvement and might or might not be
representative of the wider population of patients undergoing
PCI. Data were limited to in-hospital information, serum
creatinine was not collected in a standardized fashion, and only
the highest post-PCI value was recorded. It is likely that a
number of patients were discharged before peaking of the
serum creatinine, and our study might underestimate the
occurrence of CIN. Furthermore, patients who were excluded
due to absence of post-PCI serum creatinine ascertainment
were, in general, healthier than the study cohort, and this
Figure 5 Unadjusted and Adjusted Odds of CIN and NRD When
The unadjusted (U) (yellow) and adjusted (A) (blue) odds of CIN (A) and NRD (B)
approaches significance when CV/CCC 2 and is strongly predictive when the ratiintroduces potential selection bias. However, we observed asimilar relation in patients who underwent elective PCI and
had a low baseline risk of renal complications, and thus our
overall findings are likely extant. The total number of patients
with NRD was low, despite the overall large cohort, and our
study might be underpowered to detect differences in the
discriminatory ability of different dosing definitions that were
evaluated. The term CIN implies that contrast media are solely
responsible for all cases of renal dysfunction occurring in this
population, although this is probably incorrect. However, we
elected to use this term because there is no widely accepted
alternative term. Different contrast media have different iodine
concentration, and the total dose of iodine/CCC might be a
better strategy for contrast dosing. This measure is not rou-
tinely assessed in clinical practice, and these data were not
available for this cohort. Our study is observational in nature
and cannot ascribe causality.
In our study, over 65% of cases of CIN and 75% of NRD
occurred in the little over one-third of the patients whose
contrast dose exceeded a CV/CCC ratio of 3. Further research
CC Exceeds Given Threshold
the CV/CCC exceeds a given threshold. The adjusted risk of renal complications
Abbreviations as in Figure 2.CV/C
when
o 3.is warranted to assess whether routine incorporation of CV/
ir
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Safe Volume of Contrast Medium in PCI August 23, 2011:907–14CCC ratio in clinical practice and dedicated measures to limit
CV/CCC to 3 can translate into a reduction in CIN and
NRD.
Conclusions
Our study supports the need for minimizing contrast dose in
patients undergoing invasive cardiac procedures. A contrast
dose on the basis of CCC with a planned CV restricted to
2 CCC and not to exceed 3 CCC might be valuable
n reducing the risk of CIN and NRD.
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